Sydes, M. R., Spears, M. R., Mason, M. D., Clarke, N. W., Dearnaley, D. P., de Bono, J. S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Malik, Z. I., Jones, R., Parker, C. C., Ritchie, A. W. S., Russell, J. M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D. C., Hughes, R., McLaren, D., Lester, J. F., Nikapota, A., O'Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S. M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M. K. B., James, N. D., & , (2018). adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of oncology, 29, 1235–1248. http://access.bl.uk/ark:/81055/vdc_100098040761.0x000035